Please do take a look at the most recent Form 4's, you will see that of the 1.2M CS shares awarded about 90% of them are not vested until 06/2019. Of the 1.5M in share options ~300K are priced at $.85 and the balance are $1.00. Vesting of the vast majority of these options is .083/Month beginning 7/31/2018. I'm sorry but I disagree with your viewpoint that this is "over compensation" Further Spana and Wills cannot cash out on their shares unless they leave.
I think you misunderstood me. My point was that I wouldn’t touch PTN and that CLVLY is the one with the momentum. In no way a death trap. They have the most solid management you can get, no debt, lots of money rolling in and soon FDA approval too. They have Nasdaq international designation with the main stock trading on the ASX and depository receipts trading OTC here in the US. My point was that if you’re interested in malanocortins CLVLY is the only company worth buying. I wish PTN had better and more honest management because the MC4R potential is also very interesting.
Hi RFB, I have been in CLVLY since 1.23. Sold off a bunch over 9 bucks. CLVLF is the one with little volume. Got it too.
Right around that time I bought PTN and first bought it about the same price as CLVLY. Too bad the CEO at PTN doesn't take a lesson from those in Australia. The NY crew is doing what they do best...and they must be using plenty of the Bremelanotide.
Once the fat cats are satisfied we will make money here in PTN.